RT Journal Article
T1 Prevention of oral mucositis secondary to antineoplastic treatments in head and neck cancer by supplementation with oral glutamine.
T2 Prevención de la mucositis oral secundaria a los tratamientos antineoplásicos en el cáncer de cabeza y cuello mediante suplemento con glutamina oral.
A1 Pachón Ibáñez, Jerónimo
A1 Pereira Cunill, José Luis
A1 Osorio Gómez, Guiovana Fernanda
A1 Irles Rocamora, Jose Antonio
A1 Serrano Aguayo, Pilar
A1 Quintana Ángel, Begoña
A1 Fuentes Pradera, José
A1 Chaves Conde, Manuel
A1 Ortiz Gordillo, María José
A1 García Luna, Pedro Pablo
AB to evaluate the efficacy of glutamine in the prevention of the incidence of oral mucositis secondary to cancer therapies in patients with head and neck cancer (HNC). Secondary objectives were to know the incidence of odynophagia, interruptions of treatment and the requirements of analgesia and nasogastric tube. prospective cohort study of patients with squamous cell carcinoma of HNC treated with radiotherapy ± concomitant chemotherapy. We compared 131 patients receiving glutamine orally at a dose of 10 g/8 hours with 131 patients who did not receive it. patients not taking glutamine had a hazard ratio 1.78 times higher of mucositis (95% CI [1.01-3.16], p = 0.047). Regarding odynophagia, patients not taking glutamine had a hazard ratio 2.87 times higher (95% CI [1.62-5.18], p = 0.0003). The 19.8% of patients who did not take glutamine discontinued treatment versus6.9% of patients who took (p = 0.002). Regarding support requirements, 87.8% of patients without glutamine required analgesia versus 77.9% of patients with glutamine (p = 0.03) and nasogastric tube was indicated in 9.9% and 3.1% respectively (p = 0.02). oral glutamine in patients receiving cancer treatments for HNC prevents the incidence of oral mucositis and odynophagia, and decreases treatment interruptions and the use of analgesia and nasogastric tube.
YR 2018
FD 2018-02-27
LK http://hdl.handle.net/10668/12460
UL http://hdl.handle.net/10668/12460
LA en
DS RISalud
RD Apr 19, 2025